136 related articles for article (PubMed ID: 29445320)
1. A combined test for a generalized treatment effect in clinical trials with a time-to-event outcome.
Royston P
Stata J; 2017 Apr; 17(2):405-421. PubMed ID: 29445320
[TBL] [Abstract][Full Text] [Related]
2. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
Royston P; Parmar MK
BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
[TBL] [Abstract][Full Text] [Related]
3. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Tang Y
Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
[TBL] [Abstract][Full Text] [Related]
4. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
Huang B; Kuan PF
Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
[TBL] [Abstract][Full Text] [Related]
6. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
Jachno K; Heritier S; Wolfe R
BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
[TBL] [Abstract][Full Text] [Related]
7. Complex survival trial design by the product integration method.
Tang Y
Stat Med; 2022 Feb; 41(4):798-814. PubMed ID: 34908180
[TBL] [Abstract][Full Text] [Related]
8. Sample size calculation for multi-arm parallel design with restricted mean survival time.
Chen Y; Lam KF; Xu J
Stat Methods Med Res; 2024 Jan; 33(1):130-147. PubMed ID: 38093411
[TBL] [Abstract][Full Text] [Related]
9. Visualizing hypothesis tests in survival analysis under anticipated delayed effects.
Jiménez JL; Barrott I; Gasperoni F; Magirr D
Pharm Stat; 2024 May; ():. PubMed ID: 38708672
[TBL] [Abstract][Full Text] [Related]
10. A win ratio approach for comparing crossing survival curves in clinical trials.
Zheng S; Wang D; Qiu J; Chen T; Gamalo M
J Biopharm Stat; 2023 Jul; 33(4):488-501. PubMed ID: 36749067
[TBL] [Abstract][Full Text] [Related]
11. Quantifying treatment differences in confirmatory trials under non-proportional hazards.
Jiménez JL
J Appl Stat; 2022; 49(2):466-484. PubMed ID: 35707213
[TBL] [Abstract][Full Text] [Related]
12. Restricted mean survival time as a summary measure of time-to-event outcome.
Hasegawa T; Misawa S; Nakagawa S; Tanaka S; Tanase T; Ugai H; Wakana A; Yodo Y; Tsuchiya S; Suganami H;
Pharm Stat; 2020 Jul; 19(4):436-453. PubMed ID: 32072769
[TBL] [Abstract][Full Text] [Related]
13. Dynamic RMST curves for survival analysis in clinical trials.
Liao JJZ; Liu GF; Wu WC
BMC Med Res Methodol; 2020 Aug; 20(1):218. PubMed ID: 32854619
[TBL] [Abstract][Full Text] [Related]
14. Sample size calculation for two-arm trials with time-to-event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions.
Phadnis MA; Mayo MS
Biom J; 2021 Oct; 63(7):1406-1433. PubMed ID: 34272897
[TBL] [Abstract][Full Text] [Related]
15. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
Royston P; Parmar MK
Trials; 2014 Aug; 15():314. PubMed ID: 25098243
[TBL] [Abstract][Full Text] [Related]
16. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
17. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
Royston P; B Parmar MK
Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis of irish amyotrophic lateral sclerosis patients diagnosed from 1995-2010.
Rooney J; Byrne S; Heverin M; Corr B; Elamin M; Staines A; Goldacre B; Hardiman O
PLoS One; 2013; 8(9):e74733. PubMed ID: 24098664
[TBL] [Abstract][Full Text] [Related]
19. The current application of the Royston-Parmar model for prognostic modeling in health research: a scoping review.
Ng R; Kornas K; Sutradhar R; Wodchis WP; Rosella LC
Diagn Progn Res; 2018; 2():4. PubMed ID: 31093554
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent Tails.
Ueno K; Morita S
Ther Innov Regul Sci; 2023 May; 57(3):467-471. PubMed ID: 36596962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
